A carregar...
Should We Use PPAR Agonists to Reduce Cardiovascular Risk?
Trials of peroxisome proliferator-activated receptor (PPAR) agonists have shown mixed results for cardiovascular prevention. Fibrates are PPAR- [Formula: see text] agonists that act primarily to improve dyslipidemia. Based on low- and high-density lipoprotein cholesterol (LDL and HDL) effects, gemfi...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi Publishing Corporation
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2234387/ https://ncbi.nlm.nih.gov/pubmed/18288293 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2008/891425 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|